Enhancing Pharmacokinetics, Tumor Accumulation, and Antitumor Efficacy by Elastin-Like Polypeptide Fusion of Interferon Alpha

Design of tumor-homing and pH-responsive polypeptide–doxorubicin nanoparticles with enhanced anticancer efficacy and reduced side effects

(2015) Jin Hu et al.   CHEMICAL COMMUNICATIONS

Applications of elastin-like polypeptides in drug delivery

(2014) Sarah R. MacEwan et al.   JOURNAL OF CONTROLLED RELEASE

Targeting kidney mesangium by nanoparticles of defined size

(2011) C. H. J. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NMR Mapping of the IFNAR1-EC Binding Site on IFNα2 Reveals Allosteric Changes in the IFNAR2-EC Binding Site

(2010) Sabine Ruth Akabayov et al.   BIOCHEMISTRY

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

(2010) David R. Nelson et al.   GASTROENTEROLOGY

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

(2010) Stefan Zeuzem et al.   GASTROENTEROLOGY

Biopharmaceutical benchmarks 2010

(2010) Gary Walsh   NATURE BIOTECHNOLOGY

In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation

(2010) W. Gao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

(2008) Stefan Zeuzem et al.   HEPATOLOGY

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY